DRI Healthcare Refinances Series C Preferreds With C$108.7 Million Convertible Debenture Issue

DRI Healthcare ( ($TSE:DHT.UN) ) has provided an update.

DRI Healthcare Trust has completed a C$108.7 million private placement of convertible unsecured subordinated debentures, bearing 5.75% interest and maturing in 2031, which can be converted into trust units at a 30% premium to the recent three-day volume-weighted average price. The proceeds were entirely achieved through exchanging US$79.7 million of its outstanding 7.50% Series C preferred securities, leaving US$35.6 million still outstanding and effectively lowering its cost of capital while extending its debt maturity profile.

The refinancing shifts a significant portion of DRI Healthcare’s capital structure from higher-cost preferred securities into longer-dated, potentially equity-convertible debentures, which may strengthen the balance sheet and improve financial flexibility. This move could enhance the trust’s ability to pursue additional royalty acquisitions in the pharmaceutical sector, while the conversion feature offers investors upside participation if the unit price appreciates over time.

The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.

Spark’s Take on DHT.UN Stock

According to Spark, TipRanks’ AI Analyst, DHT.UN is a Neutral.

The score is held back most by weak and volatile financial statement quality (recent losses, negative free cash flow, and higher leverage). Offsetting this, the latest earnings call was upbeat with strong adjusted EBITDA/margins, cash receipts growth, and improved capital structure actions, while technicals are constructive and the dividend provides some support despite losses implied by the negative P/E.

To see Spark’s full report on DHT.UN stock, click here.

More about DRI Healthcare

DRI Healthcare Trust is a specialized investor in global pharmaceutical royalty monetization, having deployed more than $3.0 billion since 1989 to acquire over 75 royalties on more than 50 drugs, including Ekterly, Eylea, Keytruda, Remicade and Spinraza. Its units trade on the Toronto Stock Exchange in both Canadian dollars under the symbol DHT.UN and U.S. dollars under DHT.U, positioning the trust as a niche player in financing drug royalties across major markets.

Average Trading Volume: 33,033

Technical Sentiment Signal: Buy

Current Market Cap: C$948.4M

Find detailed analytics on DHT.UN stock on TipRanks’ Stock Analysis page.